ahlam1399
02-22-2016, 10:07 AM
BRIEF-Amgen and UCB an**unce positive top-line results from the phase 3 study of Romosozumab in postme**pausal women with Osteoporosis
* Frame study met all primary endpoints by reducing the incidence of new vertebral fracture through 12 and 24 months
http://rc.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/rc/1/rc.img (http://rc.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/rc/1/rc.htm)
http://rc.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/rc/2/rc.img (http://rc.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/rc/2/rc.htm)
http://rc.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/rc/3/rc.img (http://rc.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/rc/3/rc.htm)
http://da.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/a2.img (http://da.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/a2.htm)
http://adchoice.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/ach.img (http://adchoice.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/ach.htm)http://pi.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/a2t.imghttp://pi2.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4dc13c01/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=cHBQfJDV5aA:_DoylZvNMZc:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=cHBQfJDV5aA:_DoylZvNMZc:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=cHBQfJDV5aA:_DoylZvNMZc:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=cHBQfJDV5aA:_DoylZvNMZc:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=cHBQfJDV5aA:_DoylZvNMZc:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/cHBQfJDV5aA
* Frame study met all primary endpoints by reducing the incidence of new vertebral fracture through 12 and 24 months
http://rc.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/rc/1/rc.img (http://rc.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/rc/1/rc.htm)
http://rc.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/rc/2/rc.img (http://rc.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/rc/2/rc.htm)
http://rc.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/rc/3/rc.img (http://rc.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/rc/3/rc.htm)
http://da.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/a2.img (http://da.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/a2.htm)
http://adchoice.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/ach.img (http://adchoice.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/ach.htm)http://pi.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/a2t.imghttp://pi2.feedsportal.com/r/247392322031/u/49/f/654213/c/35217/s/4dc13c01/sc/28/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4dc13c01/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=cHBQfJDV5aA:_DoylZvNMZc:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=cHBQfJDV5aA:_DoylZvNMZc:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=cHBQfJDV5aA:_DoylZvNMZc:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=cHBQfJDV5aA:_DoylZvNMZc:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=cHBQfJDV5aA:_DoylZvNMZc:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/cHBQfJDV5aA